Perinatal exposure to mixtures of anti-androgenic chemicals causes proliferative lesions in rat prostate

Prostate

Volumn 75, Issue 2, 2015, Pages 126-140

  Boberg, Julie ^a   Johansson, Hanna K L ^a   Hadrup, Niels ^a   Dreisig, Karin ^a   Berthelsen, Line ^a   Almstrup, Kristian ^b   Vinggaard, Anne Marie ^a   Hass, Ulla ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

Aging; Androgen; Anti androgen; Cancer; Endocrine disrupters; Estrogen; Mixture toxicology; MRNA levels; Prepuberty; Prostate; Toxicity; Toxicology

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 3 (4 METHYLBENZYLIDENE)CAMPHOR; 4,4' ISOPROPYLIDENEDIPHENOL; ANTIANDROGEN; BUTYL PARABEN; ENDOCRINE DISRUPTOR; EPOXICONAZOLE; ESTROGEN; ESTROGEN RECEPTOR BETA; LINURON; MESSENGER RNA; PARACETAMOL; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PHTHALIC ACID DIBUTYL ESTER; PROCHLORAZ; PROCYMIDONE; VINCLOZOLIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; GENE; GENE EXPRESSION; GESTATION PERIOD; HISTOLOGY; IGF1 GENE; MALE; MORPHOLOGY; NONHUMAN; PBPC3 GENE; PERINATAL PERIOD; PRECANCER; PREPUBERTY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROSTATE WEIGHT; RAT; SIGNAL TRANSDUCTION; YOUNG ADULT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; NEWBORN; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; PROSTATE; PROSTATE TUMOR; TOXICITY; WISTAR RAT;

ANDROGEN ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; ENDOCRINE DISRUPTORS; FEMALE; MALE; ORGAN SIZE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR;

EID: 84923277946     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22897     Document Type: Article

References (44)

1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2014 [Epub ahead of print].
2. Venkateswaran V, Klotz LH. Diet and prostate cancer: Mechanisms of action and implications for chemoprevention. Nat Rev Urol 2010;7(8):442-453.
3. Soto AM, Sonnenschein C. Environmental causes of cancer: Endocrine disruptors as carcinogens. Nat Rev Endocrinol 2010;6(7):363-370.
4. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxiol 2007;23(3):374-382.
5. Isling LK, Boberg J, Jacobsen PR, Mandrup KR, Axelstad M, Christiansen S, Vinggaard AM, Taxvig C, Kortenkamp A, Hass U. Late life effects on rat reproductive system after developmental exposure to mixtures of endocrine disrupters. Reproduction 2014;147(4):465-476.
6. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16(5):972-978.
7. Eisenberg ML, Shy M, Walters RC, Lipshultz LI. The relationship between anogenital distance and azoospermia in adult men. Int J Androl 2012;35(5):726-730.
8. Hass U, Scholze M, Christiansen S, Dalgaard M, Vinggaard AM, Axelstad M, Metzdorff SB, Kortenkamp A. Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat. Environ Health Perspect 2007;115(Suppl 1):122-128.
9. Castaño-Vinyals G, Carrasco E, Lorente JA, Sabaté Y, Cirac-Claveras J, Pollán M Kogevinas M. Anogenital distance and the risk of prostate cancer. BJU Int 2012;110:E707-E710.
10. Christiansen S, Kortenkamp A, Axelstad M, Boberg J, Scholze M, Jacobsen PR, Faust M, Lichtensteiger W, Schlumpf M, Burdorf A, Hass U. Mixtures of endocrine disrupting contaminants modeled on human high end exposures: An exploratory study in rats. Int J Androl 2012;35:303-316.
11. Kristensen DM, Hass U, Lesné L, Lottrup G, Jacobsen PR, Desdoits-Lethimonier C, Boberg J, Petersen JH, Toppari J, Jensen TK, Brunak S, Skakkebaek NE, Nellemann C, Main KM, Jégou B, Leffers H. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod 2011;26(1):235-244.
12. Axelstad M, Christiansen S, Boberg J, Scholze M, Jacobsen PR, Isling LK, Kortenkamp A, Hass U. Mixtures of endocrine disrupting contaminants induce adverse developmental effects in preweaning rats. Reproduction 2014;147(4):489-501.
13. ECHA 2010. Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
14. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011;17(18):5844-5849.
15. Muthusamy S, Andersson S, Kim H-J. Butler R, Waage L, Bergerheim U, Gustafsson J-Å. Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA 2011;108(50):20090-20094.
16. Hartman J, Ström A, Gustafsson JÅ. Current concepts andsignificance of estrogen receptor β in prostate cancer. Steroids 2012;77(12):1262-1266.
17. Ishizaki F, Nishiyama T, Kawasaki T, Miyashiro Y, Hara N, Takizawa I, Naito M, Takahashi K. Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 2013;3(1528):1-9.
18. Shafi AA, Yen A, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Therap 2013;140(3):223-238.
19. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011;71(4):1486-1496.
20. Weihua Z, Mäkelä S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JÅ. A role of estrogen receptor β in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001;98(11):6330-6335.
21. Weihua Z, Lathe R, Warner M, Gustafsson JÅ. An endocrinepathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002;99(21):13589-13594.
22. Oliveira AG, Coelho PH, Guedes FD, Mahecha GAB, Hess RA, Oliveira CA. 5alpha-Androstane-3beta,17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats. Steroids 2007;72(14):914-922.
23. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G, Berman DM. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008;27(57):7180-7191.
24. Prins GS1, Birch L, Habermann H, Chang WY, Tebeau C, Putz O, Bieberich C. Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev 2001;13(4):241-252.
25. Prins GS, Ho SM. Early-life estrogens and prostate cancer in an animal model. J Dev Orig Health Dis 2010;1(6):365-370.
26. Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008 76(6):717-727.
27. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM. Sox9 is required for prostate development and prostate cancer initiation. Oncotraget 2012;3(6):651-663.
28. Gao N, Kenichiro I, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005;132(15):3431-3443.
29. Robinson JLL, Carroll JS. FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front Endocrinol (Lausanne) 2012;3(68):1-6.
30. Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS. Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology 2014;155(2):358-369.
31. Arase S, Ishii K, Igarashi K, Aisaki K, Yoshio Y, Matsushima A, Shimohigashi Y, Arima K, Kanno J, Sugimura Y. Endocrine disrupter bisphenol A increases in situ estrogen production in the mouse urogenital sinus. Biol Reprod 2011;84(4):734-742.
32. Metzdorff SB, Dalgaard M, Christiansen S, Axelstad M, Hass U, Kiersgaard MK, Scholze M, Kortenkamp A, Vinggaard AM. Dysgenesis and histological changes of genitals and perturbations of gene expression in male rats after in utero exposure to antiandrogen mixtures. Toxicol Sci 2007;98(1):87-98.
33. Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: I. Effects on the prostate gland. Biol Reprod 2001;65(5):1496-1505.
34. Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, Birch L. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998;139(3):874-883.
35. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho S-M, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, et al. 2004 Human prostate cancer risk factors. Cancer Suppl 101:2371-2490.
36. Ward JM, Reznik G, Stinson SF, Lattuada CP, Longfellow DG, Cameron TP. Histogenesis and morphology of naturally occurring prostatic carcinoma in the ACI/segHapBR rat. Lab Invest 1980;43:517-522.
37. Reznik G, Hamlin MH II, Ward JM, Stinson SF. Prostatic hyperplasia and neoplasia in aging F344 rats. Prostate 1981;2:261-268.
38. Isaacs JT. The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res 1984;44:5785-5796.
39. Nellemann C, Dalgaard M, Holst B, Bonefeld-Jørgensen EC, Vinggaard AM. Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor. Mol Cell Endocrinol 2005;237(1-2):25-35.
40. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006;66(11):5624-5632.
41. Kristensen DM, Lesné L, Le Fol V, Desdoits-Lethimonier C, Dejucq-Rainsford N, Leffers H, Jégou B. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. Int J Androl 2012;35(3):377-384.
42. Kristensen DM, Skalkam ML, Audouze K, Lesné L, Desdoits-Lethimonier C, Frederiksen H, Brunak S, Skakkebæk NE, Jégou B, Hansen JB, Junker S, Leffers H. Many putative endocrine disruptors inhibit prostaglandin synthesis. Environ Health Perspect 2011;119(4):534-541.
43. Beausoleil C, Ormsby JN, Gies A, Hass U, Heindel JJ, Holmer ML, Nielsen PJ, Munn S, Schoenfelder G. Low dose effects and non-monotonic dose responses for endocrine active chemicals: Science to practice workshop: Workshop summary. Chemosphere 2013;93(6):847-856.
44. Vandenberg LN. Non-monotonic dose responses in studies of endocrine disrupting chemicals: Bisphenol a as a case study. Dose Response 2013;12(2):259-276.